William Blair Issues Negative Outlook for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at William Blair cut their Q3 2025 EPS estimates for Exelixis in a research note issued to investors on Monday, October 20th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will earn $0.61 per share for the quarter, down from their previous forecast of $0.63. William Blair has a “Outperform” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS.

A number of other analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. JMP Securities reissued a “market outperform” rating and set a $50.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Leerink Partnrs raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Truist Financial dropped their target price on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. Finally, The Goldman Sachs Group assumed coverage on shares of Exelixis in a report on Wednesday, September 17th. They set a “buy” rating and a $47.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $44.53.

Exelixis Price Performance

EXEL opened at $36.13 on Wednesday. The stock has a market capitalization of $9.73 billion, a PE ratio of 17.37, a P/E/G ratio of 0.69 and a beta of 0.38. Exelixis has a 12-month low of $27.86 and a 12-month high of $49.62. The firm’s fifty day moving average price is $38.73 and its 200 day moving average price is $40.02.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. grew its position in Exelixis by 2.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock valued at $287,794,000 after buying an additional 164,134 shares in the last quarter. AQR Capital Management LLC grew its position in Exelixis by 10.3% in the 2nd quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after buying an additional 712,190 shares in the last quarter. Geode Capital Management LLC grew its position in Exelixis by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after buying an additional 28,289 shares in the last quarter. Invesco Ltd. lifted its holdings in Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock valued at $205,725,000 after acquiring an additional 1,596,948 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Exelixis by 42.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after acquiring an additional 1,580,567 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.